Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis

Peripheral Arterial Disease Clinical Trial

Official title:

Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02842424
• Other study ID #: 0139-16-ET
• Secondary ID: 00991
• Status: Recruiting
• Phase: Phase 4
• Start date: February 25, 2016
• Est. completion date: June 2026

Study information

• Verified date: May 2024
• Source: University of Nebraska
• Contact: Holly DeSpiegelaere
• Phone: 402-995-4171
• Email: Holly.DeSpiegelaere[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities. The most common clinical manifestation of PAD is claudication, i.e., a severe functional limitation identified as gait dysfunction and walking-induced leg muscle pain relieved by rest. The standard therapies for claudication include the medications cilostazol and pentoxifylline, supervised exercise therapy and operative revascularization. Recent data demonstrated that 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor Ramipril produces improvements in the walking performance of patients with claudication that are higher than those of cilostazol and pentoxifylline and similar to those produced by supervised exercise therapy and operative revascularization. The mechanisms by which Ramipril therapy produces this impressive improvement in the functional capacity of claudicating patients remain unknown. The Investigators hypothesize that treatment of claudicating PAD patients with Ramipril will improve walking performance and quality of life by improving the myopathy of the gastrocnemius. Improved myopathy is a consequence of reduced oxidative damage, reduced TGF-β1 production by vascular smooth muscle cells and reduced collagen deposition in the affected gastrocnemius.

Description:

This is an interventional study of PAD patients that exhibit claudication. The purpose of this study is to determine the potential mechanisms by which Ramipril vastly improves the walking performance of these patients. The study will be achieved through these specific aims: Specific Aim #1: Test the hypothesis that Ramipril-mediated improvements of walking parameters among patients with PAD correlate with improvements in both the morphometrics and biochemistry of myofibers in the gastrocnemius of the impaired limb. Specific Aim #2: Test the hypothesis that Ramipril-mediated improvements of walking parameters in patients with PAD correlate with reduced fibrotic events in small vessels and microvasculature, in association with reduced generalized collagen deposition and improved tissue oxygenation, in the gastrocnemius of the impaired limb. Specific Aim #3: Using adult human arterial smooth muscle cells (AHASMC), in vitro, the Investigators will test the hypothesis that the ACE inhibitor Ramipril, which acts as an antagonist of Angiotensin II type 1 receptor (ART1) stimulation by reducing tissue Angiotensin II (Ang II), impedes a mechanism in which Ang II stimulation of ART1 and exposure to hypoxia enhance proliferation of AHASMC and their production of TGF-β1 and collagen, via stimulation of phosphoinositide-3-kinase signaling and suppression of phosphatase and tensin homologue, a master regulator of cell growth. If the above hypotheses are correct, Aims #1 and #2 will demonstrate for the first time that therapy with Ramipril improves the walking performance and quality of life of claudicating PAD patients by improving the myopathy in skeletal muscle of the ischemic lower limbs. The work in Aim #3 will determine the pathways by which hypoxia and Angiotensin II cooperate to induce myopathy in the ischemic muscle. Specific agents targeting these pathways could become new treatments for claudication and for the more advanced stages of PAD characterized by leg rest pain and gangrene.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: June 2026
• Est. primary completion date: June 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. A positive history of chronic claudication,

2. Exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon,

3. Arterial occlusive disease per ankle Brachial index measurements and/or other imaging modalities,

4. Stable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control for 6 weeks.

Exclusion Criteria:

1. Rest pain or tissue loss due to PAD (Fontaine stage III and IV),

2. acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma,

3. Walking capacity significantly limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology,

4. Current use of either ACE inhibitors or angiotensin II receptor blockers,

5. Chronic kidney disease with estimated Glomerular Filtration Rate < 30 ml/min/1.73 m2,

6. History of bilateral severe renal artery stenosis and 7) History of angioedema related to previous ACE-inhibitor treatment or known hypersensitivity to ramipril or other ACE inhibitors.

Related Conditions & MeSH terms

• Intermittent Claudication
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Drug:
• Ramipril
Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.

Locations

Country	Name	City	State
United States	VA Medical Center	Omaha	Nebraska

Sponsors (1)

Lead Sponsor	Collaborator
University of Nebraska

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute Claudication Distance	Maximum walking distance in meters per Gardner protocol	6 months
Secondary	6-minute Walking Distance	Maximum Distance in meters the patient can walk in 6 minutes on a flat, hard surface	6 months
Secondary	Initial Claudication Distance	The distance in meters the patient can walk before he experiences claudication pain, per Gardner protocol	6 months
Secondary	Average Daily Steps Taken	Monitored with an accelerometer at home	6 months
Secondary	Quality of life measured by the Walking Impairment Questionnaire	There are 14 questions across three categories of walking distance, walking speed and stair climbing. The WIQ is graded on a scale of 0-4; 0 represents no difficulty; 4 represents inability to walk. 0 score represents no difficulty, 1 score is slight difficulty, 2 score is some difficulty, 3 score is much difficulty, 4 score is unable to complete the task in question.	6 months
Secondary	Quality of life measured by the Medical Outcomes Study Short Form 36 Healthy Survey	- (The Short Form 36 Health Survey Questionnaire) has 8 scale (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health) that measures quality of life. The SF-36 scoring ranges from 0-100. Higher scores indicate better health; lower scores indicate more disability	6 months
Secondary	Leg biomechanics measured as Vertical ground reaction force	measured as Vertical ground reaction force	6 months
Secondary	Leg hemodynamics measured as Ankle Brachial Index (ABI)	Ratio of the blood pressure at the level of the ankle to the blood pressure at the level of the arm	6 months
Secondary	Leg hemodynamics	measured as Calf blood flow via contrast-enhanced ultrasound	6 months
Secondary	Leg hemodynamics measured as Calf blood flow via stress ABI testing	measured as Calf blood flow via stress ABI testing	6 months
Secondary	Leg hemodynamics measured as Calf muscle hemoglobin oxygen saturation	Measured with Near Infrared Spectroscopy	6 months
Secondary	Myofiber Mitochondrial Respiration, measured by polarography	measured by polarography	6 months
Secondary	Muscle Mitochondrial Function, measured by spectrophotometry	measured by spectrophotometry	6 months
Secondary	Myofiber Oxidative Damage	Myofiber content of HNE adducts and protein carbonyls	6 months
Secondary	Myofiber Morphology, Cross-Sectional Area	Area in square microns, measured by immunofluorescence microscopy	6 months
Secondary	Myofiber Morphology, Roundness	Measured as ratio of major axis in microns to minor axis in microns	6 months
Secondary	Myofiber Morphology, Solidity	Measured as the ratio of myofiber area in square microns to the area of a fitted convex hull in square microns	6 months
Secondary	Muscle Fibrosis, Muscle TGF-ß1	Measured as the sum of the products of mean pixel intensity (in gray scale units) and area (in square microns) of each TGF-ß1 labeled event divided by the total area (in square microns) of the tissue sample analyzed. Measured by immunofluorescence microscopy.	6 months
Secondary	Muscle Fibrosis, Total collagen deposited.	Measured as the area-weighted mean pixel intensity (in gray scale units) of all the collagen labeled events per tissue sample. Measured by bright-field microscopy.	6 months
Secondary	Microvascular Fibrosis, Capillary wall thickness.	Measured in microns by immunofluorescence microscopy of vessels labeled for collagen.	6 months
Secondary	Capillary density.	Number of capillaries per unit area (in square microns) of the tissue sample analyzed.	6 months
Secondary	Serum biomarker of fibrosis, serum procollagen type I c-peptide in picograms of peptide per ml	serum procollagen type I c-peptide in picograms of peptide	6 months
Secondary	Serum biomarker of fibrosis, serum procollagen type III n-terminal peptide in picograms of peptide per ml	serum procollagen type III n-terminal peptide in picograms of peptide per ml	6 months
Secondary	Plasma biomarker of fibrosis, plasma TGF-ß1 in picograms per ml	plasma TGF-ß1 in picograms per ml	6 months